Want full text access to this journal?
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
Benard P Dreyer
No abstract text is available yet for this article.
September 11, 2019: New England Journal of Medicine
#2
EDITORIAL
Carl H June
No abstract text is available yet for this article.
September 11, 2019: New England Journal of Medicine
#3
EDITORIAL
Henna Tyynismaa
No abstract text is available yet for this article.
September 11, 2019: New England Journal of Medicine
#4
Lei Xu, Jun Wang, Yulin Liu, Liangfu Xie, Bin Su, Danlei Mou, Longteng Wang, Tingting Liu, Xiaobao Wang, Bin Zhang, Long Zhao, Liangding Hu, Hongmei Ning, Yufeng Zhang, Kai Deng, Lifeng Liu, Xiaofan Lu, Tong Zhang, Jun Xu, Cheng Li, Hao Wu, Hongkui Deng, Hu Chen
The safety of CRISPR (clustered regularly interspaced short palindromic repeats)-based genome editing in the context of human gene therapy is largely unknown. CCR5 is a reasonable but not absolutely protective target for a cure of human immunodeficiency virus type 1 (HIV-1) infection, because CCR5 -null blood cells are largely resistant to HIV-1 entry. We transplanted CRISPR-edited CCR5 -ablated hematopoietic stem and progenitor cells (HSPCs) into a patient with HIV-1 infection and acute lymphoblastic leukemia...
September 11, 2019: New England Journal of Medicine
#5
Marin L Gantner, Kevin Eade, Martina Wallace, Michal K Handzlik, Regis Fallon, Jennifer Trombley, Roberto Bonelli, Sarah Giles, Sarah Harkins-Perry, Tjebo F C Heeren, Lydia Sauer, Yoichiro Ideguchi, Michelle Baldini, Lea Scheppke, Michael I Dorrell, Maki Kitano, Barbara J Hart, Carolyn Cai, Takayuki Nagasaki, Mehmet G Badur, Mali Okada, Sasha M Woods, Catherine Egan, Mark Gillies, Robyn Guymer, Florian Eichler, Melanie Bahlo, Marcus Fruttiger, Rando Allikmets, Paul S Bernstein, Christian M Metallo, Martin Friedlander
BACKGROUND: Identifying mechanisms of diseases with complex inheritance patterns, such as macular telangiectasia type 2, is challenging. A link between macular telangiectasia type 2 and altered serine metabolism has been established previously. METHODS: Through exome sequence analysis of a patient with macular telangiectasia type 2 and his family members, we identified a variant in SPTLC1 encoding a subunit of serine palmitoyltransferase (SPT). Because mutations affecting SPT are known to cause hereditary sensory and autonomic neuropathy type 1 (HSAN1), we examined 10 additional persons with HSAN1 for ophthalmologic disease...
September 11, 2019: New England Journal of Medicine
#6
Daniel F Hayes
No abstract text is available yet for this article.
September 10, 2019: New England Journal of Medicine
#7
LETTER
Sean D Maddock, Meghan M Cirulis, Sean J Callahan, Lynn M Keenan, Cheryl S Pirozzi, Sanjeev M Raman, Scott K Aberegg
No abstract text is available yet for this article.
September 6, 2019: New England Journal of Medicine
#8
Jennifer E Layden, Isaac Ghinai, Ian Pray, Anne Kimball, Mark Layer, Mark Tenforde, Livia Navon, Brooke Hoots, Phillip P Salvatore, Megan Elderbrook, Thomas Haupt, Jeffrey Kanne, Megan T Patel, Lori Saathoff-Huber, Brian A King, Josh G Schier, Christina A Mikosz, Jonathan Meiman
BACKGROUND: E-cigarettes are battery-operated devices that heat a liquid and deliver an aerosolized product to the user. Pulmonary illnesses related to e-cigarette use have been reported, but no large series has been described. In July 2019, the Wisconsin Department of Health Services and the Illinois Department of Public Health received reports of pulmonary disease associated with the use of e-cigarettes (also called vaping) and launched a coordinated public health investigation. METHODS: We defined case patients as persons who reported use of e-cigarette devices and related products in the 90 days before symptom onset and had pulmonary infiltrates on imaging and whose illnesses were not attributed to other causes...
September 6, 2019: New England Journal of Medicine
#9
EDITORIAL
David C Christiani
No abstract text is available yet for this article.
September 6, 2019: New England Journal of Medicine
#10
LETTER
Travis S Henry, Jeffrey P Kanne, Seth J Kligerman
No abstract text is available yet for this article.
September 6, 2019: New England Journal of Medicine
#11
Stacie B Dusetzina, Nancy L Keating, Haiden A Huskamp
No abstract text is available yet for this article.
September 4, 2019: New England Journal of Medicine
#12
Richard G Frank, Len M Nichols
No abstract text is available yet for this article.
September 4, 2019: New England Journal of Medicine
#13
Daniel M F Claassens, Gerrit J A Vos, Thomas O Bergmeijer, Renicus S Hermanides, Arnoud W J van 't Hof, Pim van der Harst, Emanuele Barbato, Carmine Morisco, Richard M Tjon Joe Gin, Folkert W Asselbergs, Arend Mosterd, Jean-Paul R Herrman, Willem J M Dewilde, Paul W A Janssen, Johannes C Kelder, Maarten J Postma, Anthonius de Boer, Cornelis Boersma, Vera H M Deneer, Jurriën M Ten Berg
BACKGROUND: It is unknown whether patients undergoing primary percutaneous coronary intervention (PCI) benefit from genotype-guided selection of oral P2Y12 inhibitors. METHODS: We conducted a randomized, open-label, assessor-blinded trial in which patients undergoing primary PCI with stent implantation were assigned in a 1:1 ratio to receive either a P2Y12 inhibitor on the basis of early CYP2C19 genetic testing (genotype-guided group) or standard treatment with either ticagrelor or prasugrel (standard-treatment group) for 12 months...
September 3, 2019: New England Journal of Medicine
#14
Satoshi Yasuda, Koichi Kaikita, Masaharu Akao, Junya Ako, Tetsuya Matoba, Masato Nakamura, Katsumi Miyauchi, Nobuhisa Hagiwara, Kazuo Kimura, Atsushi Hirayama, Kunihiko Matsui, Hisao Ogawa
BACKGROUND: There are limited data from randomized trials evaluating the use of antithrombotic therapy in patients with atrial fibrillation and stable coronary artery disease. METHODS: In a multicenter, open-label trial conducted in Japan, we randomly assigned 2236 patients with atrial fibrillation who had undergone percutaneous coronary intervention (PCI) or coronary-artery bypass grafting (CABG) more than 1 year earlier or who had angiographically confirmed coronary artery disease not requiring revascularization to receive monotherapy with rivaroxaban (a non-vitamin K antagonist oral anticoagulant) or combination therapy with rivaroxaban plus a single antiplatelet agent...
September 2, 2019: New England Journal of Medicine
#15
EDITORIAL
Richard C Becker
No abstract text is available yet for this article.
September 2, 2019: New England Journal of Medicine
#16
Stefanie Schüpke, Franz-Josef Neumann, Maurizio Menichelli, Katharina Mayer, Isabell Bernlochner, Jochen Wöhrle, Gert Richardt, Christoph Liebetrau, Bernhard Witzenbichler, David Antoniucci, Ibrahim Akin, Lorenz Bott-Flügel, Marcus Fischer, Ulf Landmesser, Hugo A Katus, Dirk Sibbing, Melchior Seyfarth, Marion Janisch, Duino Boncompagni, Raphaela Hilz, Wolfgang Rottbauer, Rainer Okrojek, Helge Möllmann, Willibald Hochholzer, Angela Migliorini, Salvatore Cassese, Pasquale Mollo, Erion Xhepa, Sebastian Kufner, Axel Strehle, Stefan Leggewie, Abdelhakim Allali, Gjin Ndrepepa, Helmut Schühlen, Dominick J Angiolillo, Christian W Hamm, Alexander Hapfelmeier, Ralph Tölg, Dietmar Trenk, Heribert Schunkert, Karl-Ludwig Laugwitz, Adnan Kastrati
BACKGROUND: The relative merits of ticagrelor as compared with prasugrel in patients with acute coronary syndromes for whom invasive evaluation is planned are uncertain. METHODS: In this multicenter, randomized, open-label trial, we randomly assigned patients who presented with acute coronary syndromes and for whom invasive evaluation was planned to receive either ticagrelor or prasugrel. The primary end point was the composite of death, myocardial infarction, or stroke at 1 year...
September 1, 2019: New England Journal of Medicine
#17
P Gabriel Steg, Deepak L Bhatt, Tabassome Simon, Kim Fox, Shamir R Mehta, Robert A Harrington, Claes Held, Marielle Andersson, Anders Himmelmann, Wilhelm Ridderstråle, Maria Leonsson-Zachrisson, Yuyin Liu, Grzegorz Opolski, Dmitry Zateyshchikov, Junbo Ge, José C Nicolau, Ramón Corbalán, Jan H Cornel, Petr Widimský, Lawrence A Leiter
BACKGROUND: Patients with stable coronary artery disease and diabetes mellitus who have not had a myocardial infarction or stroke are at high risk for cardiovascular events. Whether adding ticagrelor to aspirin improves outcomes in this population is unclear. METHODS: In this randomized, double-blind trial, we assigned patients who were 50 years of age or older and who had stable coronary artery disease and type 2 diabetes mellitus to receive either ticagrelor plus aspirin or placebo plus aspirin...
September 1, 2019: New England Journal of Medicine
#18
EDITORIAL
Eric R Bates
No abstract text is available yet for this article.
September 1, 2019: New England Journal of Medicine
#19
EDITORIAL
Lars Køber, Thomas Engstrøm
No abstract text is available yet for this article.
September 1, 2019: New England Journal of Medicine
#20
Shamir R Mehta, David A Wood, Robert F Storey, Roxana Mehran, Kevin R Bainey, Helen Nguyen, Brandi Meeks, Giuseppe Di Pasquale, Jose López-Sendón, David P Faxon, Laura Mauri, Sunil V Rao, Laurent Feldman, P Gabriel Steg, Álvaro Avezum, Tej Sheth, Natalia Pinilla-Echeverri, Raul Moreno, Gianluca Campo, Benjamin Wrigley, Sasko Kedev, Andrew Sutton, Richard Oliver, Josep Rodés-Cabau, Goran Stanković, Robert Welsh, Shahar Lavi, Warren J Cantor, Jia Wang, Juliet Nakamya, Shrikant I Bangdiwala, John A Cairns
BACKGROUND: In patients with ST-segment elevation myocardial infarction (STEMI), percutaneous coronary intervention (PCI) of the culprit lesion reduces the risk of cardiovascular death or myocardial infarction. Whether PCI of nonculprit lesions further reduces the risk of such events is unclear. METHODS: We randomly assigned patients with STEMI and multivessel coronary artery disease who had undergone successful culprit-lesion PCI to a strategy of either complete revascularization with PCI of angiographically significant nonculprit lesions or no further revascularization...
September 1, 2019: New England Journal of Medicine
Fetching more papers... 
